Related Experiment Video

Updated: Oct 26, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.5K

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

Mridula A George1, Sadaf Qureshi2, Coral Omene1

  • 1Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.

Frontiers in Oncology
|July 30, 2021
PubMed

Insights

Cyclin Dependent Kinase 4 and 6 (CDK 4/6) inhibitors like palbociclib, ribociclib, and abemaciclib improve outcomes for metastatic hormone receptor-positive breast cancer. This review details their preclinical and pharmacological differences, aiding in understanding their use in specific patient groups.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic hormone receptor (HR) positive breast cancer prognosis is improved by Cyclin Dependent Kinase 4 and 6 (CDK 4/6) inhibitors.
  • These targeted therapies overcome resistance to traditional endocrine therapy.

Purpose of the Study:

  • To explore preclinical and pharmacological differences among approved CDK 4/6 inhibitors (palbociclib, ribociclib, abemaciclib).
  • To understand the distinct clinical benefits of these agents in specific patient subgroups with metastatic HR-positive breast cancer.

Main Methods:

  • Review of preclinical data.
  • Analysis of pharmacological profiles.
  • Examination of clinical scenarios including monotherapy, brain metastases, and adjuvant settings.

Main Results:

  • While all CDK 4/6 inhibitors target the same pathway, distinct properties exist between palbociclib, ribociclib, and abemaciclib.
  • These differences may explain observed variations in efficacy and application across different clinical contexts.

Conclusions:

  • Understanding the nuanced differences between CDK 4/6 inhibitors is crucial for optimizing treatment selection.
  • Personalized therapeutic strategies can be developed for metastatic HR-positive breast cancer based on agent-specific characteristics and patient profiles.
Keywords:
CDK4/6 cell cycle inhibitorsCDK4/6 inhibitors in breast cancerabemaciclibhormone receptor (HR)metastatic breast cancerpalbociblibribociclib

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.8K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K